Tevogen Bio Holdings Inc. (TVGN)

US — Healthcare Sector
Peers: SRZN  ATOS  CGTX  WHWK  GLSI  TIL  ONCY  HURA  CLNN  MGNX 

Automate Your Wheel Strategy on TVGN

With Tiblio's Option Bot, you can configure your own wheel strategy including TVGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation's Health and Prosperity
TVGN
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral

CEO of Tevogen Bio, Dr. Saadi addresses short selling and its potential impact on the nation's health and prosperity. Reaffirms commitment to shareholders.

Read More
image for news Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation's Health and Prosperity
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
TVGN
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

WARREN, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, congratulates Robert F. Kennedy Jr.'s as he begins his role at the head of Health and Human Services.

Read More
image for news Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
TVGN
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral

WARREN, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), is a clinical-stage specialty immunotherapy biotech company. As the biopharma industry faces increasing competition from international markets and an evolving regulatory landscape, Tevogen Bio's innovative business model positions it as a potential leader in the shift towards cost-efficient, value-driven healthcare.

Read More
image for news Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

About Tevogen Bio Holdings Inc. (TVGN)

  • IPO Date 2022-01-05
  • Website https://tevogen.com
  • Industry Biotechnology
  • CEO Ryan H. Saadi
  • Employees 18

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.